The first RNAi medicines are entering the market, showing pioneer of the drug class Klaus Charissé (Alnylam) that the RNAi revolution is taking hold.
Privately-owned hearing aid company WS Audiology, which grew out of the merger between Widex and Sivantos, plans to list Hear.com, which handles online sales.
Outside the US, Darzalex sales are going so well that they are close to overtaking US sales for Q1. In total, sales amounted to USD 1.37, from which Genmab receives royalties.
Denmark is currently discussing swapping the Astrazeneca vaccine for other vaccines with multiple countries.
Canadian authorities have approved the use of Darzalex, which is Genmab-developed, for treating the rare disease amyloidosis.
Denmark’s decision to stop using the Astrazeneca vaccine is one that health organizations can understand, However, they say it can prolong the corona crisis – and sends a poor signal to others.
Allergy company ALK has received the green light from the FDA to expand the use of its ragweed allergy tablet to include children. The approval is "significant" on the US market, where ALK has yet to make its big breakthrough.
With the recently approved sclerosis treatment, Kesimpta, first developed by Genmab, Novatis is in full swing competing with Roche's dominant medicine on the market. Now Roche attempts retaliation.
It is good news that the FDA has approved ALK's ragweed allergy tablet for use in children – though it won't cause a huge increase in short term sales, says Sydbank senior analyst Søren Løntoft Hansen.
Hearing aid company WS Audiology takes first place in the top 30 of patent applicants in conventional hearing aid technology, according to new report. The company credits its concentrated patent strategy, and now, it will also increase its patent efforts in Asian markets.
Ambu's many product launches provide beneficial opportunities for Ambu, according to analyst group at investment banking company Morgan Stanley.
Recent concerns on whether Denmark is properly protected in terms of access to vaccines have been implemented in the new national Danish life science strategy which was presented early Friday. The strategy mentions partnerships with the life science industry to strengthen vaccine access.
The EU is negotiating with Pfizer/Biontech and Moderna for new vaccine contracts, states French economy minister, but it's unlikely the union it will reach out to Astrazeneca or Johnson & Johnson.
Miss anything?
The fact that many countries around the world are pausing the vaccine from Astrazeneca has no financial consequences for the pharmaceutical giant, according to the country director of Denmark and Norway. However, he does not rule out that the vaccine might suddenly be turned into a lucrative business.
The Danish Health Authority deems that the continued use of the 200,000 Astrazeneca vaccines which Denmark has in stock will prevent one hospitalization but lead to five blood clots.
Genmab CEO Jan van de Winkel is not keen on commenting on the possibility of a settlement in the dispute between Genmab and partner Janssen concerning the distribution of earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.
According to the WHO, Denmark is looking into the possibility of sharing its doses of the Astrazeneca vaccine with developing countries after the vaccine has been discontinued in the Danish vaccine program.
Gilead Sciences has got a green light from the US Food and Drug Administration to use the drug Trodelvy for treating metastatic urothelial cancer. This is the second approval in a short time, as Trodelvy was recently approved for treating breast cancer.
Against its will, the board of GN Store has to review whether the company has to provide tax reports on a country-per-country basis starting next year. This was the verdict at the firm's general assembly.
In collaboration with Zealand Pharma, Boehringer Ingelheim is advancing to stage II trials with the drug candidate BI 456906 which is currently being tested as a treatment for type II diabetes. Now, the drug will prove its worth as a treatment for the fatty liver disease NASH and obesity.
The statutory pension fund ATP, which holds a portion of Genmab's shares, is particularly critical of the variable part of Genmab's salary packages for the executive team and board of directors. However the proposed changes to the salaries were accepted without further issue.
Hearing aid company GN Hearing maintains its guidance for 2021 from the firm's presentation of its annual report in February. Thus, it forecasts that its revenue will grow more than 25 percent organically.
At a press conference, the Danish Health Authority states that the vaccine from Astrazeneca will be removed from Denmark's vaccination program.
Even though Rexulti did not deliver quick results in phase III against Alzheimer's disease, Lundbeck's Head of R&D Johan Luthman still sees plenty of potential in the trial which is now set to be concluded in the new year.
Business Process Manager - Orifarm 
Mechanical Design Engineer, with solid experience in 3D CAD 
eTMF Manager - Genmab 
Pharmacovigilance Director - Zealand Pharma R&D Process Manager - Genmab Regulatory Affairs Specialist - Orifarm 
Pharmacovigilance Auditor - ALK Electronics / HW Engineer for the development of medical devices 
Statistical Programmer, Specialist - Lundbeck Development Chemist for Drug Product Development - ALK 
Senior QA Manager, QA Commercial Operations, Ascendis Pharma 
System Engineer for novel stem cell devices - Novo Nordisk Regulatory Affairs Associate - Orifarm 
Associate Director, GMP QA, Commercial Operations – Y-mAbs Therapeutics Senior QMS Professional in Project- and Change Management - ALK Sponsor Oversight Lead - Genmab Manager, SOX Compliance - Zealand Pharma Senior Laborant with responsibility for operation and task coordination Cross Functional CMC/Safety Toxicologist, Ascendis Pharma Senior Scientist (Toxicology) / Nonclinical Safety Specialist Senior Scientist, Neuroimmunology and Neuroinflammation, In-vivo, Lundbeck 
Director of Global Marketing - Ascelia Pharma Senior Manager, Regulatory Affairs CMC, New Markets & Life Cycle Management - Y-mAbs Therapeutics Project Manager, Unilabs Senior Manager, QA GMP - Genmab 
